You are here: Industry Insights > nivolumab

News List

Scottish Medicines Consortium approves three cancer drugs for NHS use Pharmaceutical-Technology
December 20, 2021
The Scottish Medicines Consortium (SMC) has approved three drugs for use on the National Health Service (NHS) Scotland to treat advanced ovarian, bowel cancer and Waldenström’s macroglobulinaemia.
Press Release Seagen Announces Preliminary Results from Phase 2 Clinical Trial of ADCETRIS (brentuximab vedotin) in Novel Combination of Agents for Patients with Advanced Stage Classical Hodgkin Lymph FirstWordPharma
December 13, 2021
Frontline Treatment with ADCETRIS in Combination with Nivolumab, Doxorubicin and Dacarbazine (AN+AD) Shows a Complete Response Rate of 88%, Overall Response Rate of 93% and Favorable Safety Profile.
Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore prnasia
October 28, 2021
Adagene Inc. ("Adagene") (Nasdaq: ADAG), the National University Cancer Institute, Singapore (NCIS) at the National University Hospital in Singapore, National Cancer Centre Singapore (NCCS)...
Kintor Pharma Announces China NMPA Approves Clinical Trial of ALK-1 and Nivolumab Combination Therapy for the First-line Treatment of Advanced Hepatocellular Carcinoma prnasia
October 13, 2021
Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics...
FDA Approves Nivolumab for Resected Esophageal or GEJ Cancer americanpharmaceuticalreview
May 24, 2021
On May 20, 2021, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) for patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease who have received ...
NICE nod for BMS’ Opdivo in advanced oesophageal cancer pharmatimes
May 17, 2021
The UK National Institute for Health and Care Excellence (NICE) has recommended Bristol Myers Squibb’s (BMS) Opdivo for the treatment of unresectable advanced oesophageal squamous cell cancer (OSCC).
FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma americanpharmaceuticalreview
January 28, 2021
The U.S. Food and Drug Administration (FDA) approved the combination of nivolumab (Opdivo, Bristol-Myers Squibb) and cabozantinib (Cabometyx, Exelixis) as first-line treatment for patients with advanced renal cell carcinoma (RCC).
NICE rules nivolumab is not cost effective for use on NHS europeanpharmaceuticalreview
November 10, 2020
The regulatory body said that due to uncertainties surrounding the long-term effectiveness of nivolumab (Opdivo), its cost-effectiveness estimates are too high.
VBL Enrolls First Patients in VB-111 Trial for Metastatic Colorectal Cancer americanpharmaceuticalreview
September 18, 2020
VBL Therapeutics announced the first two patients have been enrolled in the Phase 2 clinical trial of VB-111 in combination with nivolumab (Opdivo®), an immune checkpoint inhibitor, for the treatment of metastatic colorectal cancer.
FDA Approves Nivolumab plus Ipilimumab, Chemotherapy for Metastatic NSCLC americanpharmaceuticalreview
June 03, 2020
The Food and Drug Administration (FDA) approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb) plus ipilimumab (YERVOY, Bristol-Myers Squibb) ...

Previous page 1 2 3 Next page